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ABSTRACT
HER2-positive breast tumors are associated with a high risk of brain relapse. HER3 
is thought to be an indispensible signaling substrate for HER2 (encoded by ERBB2) 
and is induced in breast cancer-brain metastases, though the molecular mechanisms 
by which this oncogenic dimer promotes the development of brain metastases are 
still elusive. We studied the effects of the HER3-HER2 ligand, heregulin (neuregulin-1, 
broadly expressed in the brain), on luminal breast cancer cell lines in vitro. Treatment 
of SKBr3 (ERBB2-amplified), MDA-MB-361 (ERBB2-amplified, metastatic brain tumor-
derived) and MCF7 (HER2-positive, not ERBB2-amplified) cells with exogenous 
heregulin increased proliferation and adhesive potential, concomitant with induction 
of cyclin D1 and ICAM-1, and suppression of p27. All three cell lines invaded through 
matrigel toward a heregulin chemotactic signal in transwell experiments, associated 
with activation of extracellular cathepsin B and matrix metalloproteinase-9 (MMP-9). 
Moreover, heregulin induced breast cancer cell transmigration across a tight barrier 
of primary human brain microvascular endothelia. This was dependent on the activity 
of HER2, HER3 and MMPs, and was completely abrogated by combination HER2-HER3 
blockade using Herceptin® and the humanized HER3 monoclonal antibody, EV20. 
Collectively these data suggest mechanisms by which the HER3-HER2 dimer promotes 
development of metastatic tumors in the heregulin-rich brain microenvironment.
INTRODUCTION
The development of brain metastases is a 
growing public health problem affecting more than 
100,000 patients in the United States every year [1], 
including 10–30% of breast cancer patients [2, 3]. 
This complication is associated with severe morbidity 
and virtually 100% mortality, as currently there is no 
treatment strategy with proven efficacy. HER2-positive 
breast cancer patients are at particularly high risk [4, 5], 
with around half developing brain metastases during 
the course of disease [6]. HER2-targeted drug therapies 
delay the onset of brain metastases in these patients, and 
improve median survival after a diagnosis of metastatic 
brain relapse [7–10]. These observations indicate that 
HER2 plays a critical role in brain relapse. However, the 
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molecular mechanisms underpinning this relationship 
have not been investigated in detail.
HER2 is an orphan member of the human epidermal 
growth factor receptor (HER/ERBB) family. It undergoes 
obligate heterodimerization with HER3, and to a lesser 
extent HER4 and EGFR [11–14]. The HER3-HER2 
dimer is regarded as the major oncogenic unit in HER2-
positive breast cancer [11, 15, 16]. Ligand-activated dimers 
transduce potent survival and proliferation signals through 
the PI3K-AKT and ERK1/2 pathways [11, 17]. HER3 has 
two ligands: Heregulin (HRG; also known as neuregulin-1 
(NRG1)) and neuregulin-2. HRG is the better studied of 
the two and is broadly expressed in the brain by neurons, 
glia and the cerebral endothelium, functioning to promote 
survival, differentiation, migration and cytoprotection 
[18–20]. At least 17 HRG isoforms have been described, 
including secreted, membrane-bound and nuclear 
‘back-signaling’ isoforms that are generated through a 
combination of alternate transcription start sites, splicing 
and post-translational processing [21]. Importantly, 
primary breast cancers that over-express HER3 are 
associated with a significantly higher rate of isolated brain 
metastases [22], and induction of HER3 is associated with 
development of brain metastases from both breast and lung 
cancers [23, 24]. Despite this, the functional relationships 
between HRG, HER3 and HER2 in breast cancer-brain 
metastases have not been elucidated.
HRG and HER2 signaling can also induce certain 
matrix metalloproteinase enzymes (MMPs) [25–28]. 
MMPs are zinc-dependent endopeptidases that degrade 
extracellular matrix (ECM) proteins. Their activities 
facilitate various normal physiologic processes (e.g. 
wound healing and organ development), and their 
dysregulation can be associated with pathological 
processes, including progression-associated changes 
in the tumor microenvironment. Regulation of MMP 
expression and activity is complex – they are expressed 
and stored as zymogens, secreted and activated on-
demand by ‘convertases’ including other MMPs, and 
in vivo, their activities are fine-tuned according to the 
local balance between MMPs, TIMPs (tissue inhibitors 
of metalloproteinases) and other physiologic inhibitors 
[29] (e.g. the metastasis suppressor, RECK [30]). 
Therefore measurement of MMP expression is not a 
reliable surrogate for function. MMPs have been strongly 
implicated in the development of brain metastases from 
breast cancer [31–35]. For example, expression of MMP-9 
is relatively higher in the brain-seeking MDA-MB-231 
breast cancer cell line variant compared to parental and 
bone-homing counterparts [36], and ectopic expression of 
MMP-2 in MDA-MB-231 cells increased the incidence of 
brain metastases after intracardiac injection [37].
In order to establish distant brain metastases, 
disseminated breast cancer cells must initially traverse 
the blood-brain-barrier: a specialized endothelium that is 
resistant to diffusion of hydrophilic or large molecules by 
virtue of endothelial tight-junctions that are unique to the 
central nervous system. This specialized microvasculature 
is in close contact with astrocytic foot processes, pericytes 
and a thick basement membrane, which collectively 
facilitate the high substrate selectivity that is necessary to 
protect brain tissue from circulating pathogens and toxins, 
including chemotherapeutic agents [38, 39]. Extravasation 
of tumor cells across this barrier is therefore thought to 
be an active process. Following extravasation, tumor cells 
must establish growth-promoting interactions with the 
neural niche [40–43].
This study aimed to investigate molecular 
mechanisms by which HER3-HER2 signaling may 
promote the development of brain metastases from breast 
cancer. In light of the inferred associations between 
HER3, HER2, MMP activity and brain metastases, and 
the ubiquitous expression of heregulin in the brain, we 
hypothesized that heregulin may activate molecular 
mechanisms conducive to the establishment and growth 
of HER2-positive breast cancer cells in the brain 
microenvironment.
RESULTS
Expression of ERBB3 and NRG1 isoforms in 
breast cancer cell lines
To characterize the expression of heregulin (NRG1 
gene) and HER3 (ERBB3 gene) in breast cancer cell line 
models, and select the most appropriate lines for functional 
experiments, we investigated the relative baseline mRNA 
expression levels of ERBB3 and NRG1 (α and β heregulin 
splice isoforms) in a large panel of breast cancer cell lines 
by quantitative reverse transcription-PCR (qRT-PCR). The 
gene expression profile-based molecular subtypes of these 
cell lines (luminal, luminal-ERBB2-amplified, basal-A and 
basal-B/claudin-low) were derived from published reports 
[44–46], marked in Figure 1. This screening experiment 
revealed an inverse association between ERBB3 and NRG1 
expression, with highest levels of ERBB3 in luminal cell 
lines, and highest levels of NRG1 in claudin-low cell lines, 
consistent with their mesenchymal-like phenotype [46] 
(Figure 1). ERBB3/NRG1 expression phenotypes were 
mixed in basal-A cell lines.
Paracrine activation of HER2-HER3 in luminal 
breast cancer cell lines
We next investigated the responses of three 
representative ERBB3-expressing cell lines to treatment with 
exogenous heregulin (HRG): MDA-MB-361, MCF7 and 
SKBr3. These three cell lines are luminal-like when stratified 
based on transcriptomic profile [44–46]. Other key features 
to note are that MDA-MB-361 and SKBr3 harbor ERBB2 
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amplification, MDA-MB-361 was isolated from a breast 
cancer-derived metastatic brain tumor, and SKBr3 cells do 
not express estrogen receptor (ER-negative) [44]. All three 
lines are capable of colonizing the brain in animal models 
([47, 48] and unpublished observations).
To begin to examine the effects of exogenous HRG, 
cells were deprived of serum (‘serum-starved’) before 
HRG treatment, since serum contains many growth 
factors including HRG itself. Forty-eight hours of HRG 
treatment resulted in noticeable morphological changes, 
including stellate features and pseudopodia formation by 
MCF7 and SKBr3 cells (Figure 2A), consistent with other 
reports suggesting HRG treatment induces an epithelial-
to-mesenchymal phenotypic shift in these cell lines 
[49, 50]. Morphologic change for MDA-MB-361 was 
consistent with the other two cell lines but more subtle 
overall, with cells becoming less cohesive and developing 
some stellate projections.
We also investigated HER3-HER2 downstream 
signaling 30 min after HRG treatment. All three cell lines 
responded to exogenous HRG with phosphorylation of 
HER3 and its preferred dimerization partner HER2, but 
not the other HRG receptor HER4 (Figure 2B). There was 
also HRG-induced phosphorylation of AKT and ERK1/2, 
important downstream targets of HER2 that regulate tumor 
cell survival, proliferation and invasion [17]. Though 
of lesser magnitude than the phosphorylation induction, 
there was also an increase in total HER3 protein levels. 
The short time frame of this experiment suggests this may 
involve post-transcriptional mechanisms, such as protein 
stabilization or translation efficiency.
In contrast to the HER2/HER3-positive luminal cell 
lines, three representative claudin-low cell lines (Hs578T, 
MDA-MB-231 and SUM-159-PT; Figure 1) did not 
show induction of HER3 expression or phosphorylation 
following treatment with exogenous HRG (Supplementary 
Figure 1).
Exogenous HRG treatment induces cell line-
dependent proliferation and adhesion of luminal 
breast cancer cells in vitro
Since AKT and ERK1/2 were potently activated 
by HRG in three luminal breast cancer cell lines and 
they are known to induce tumor cell proliferation in 
other contexts [51], we investigated the effects of 
HRG on proliferation of HRG-treated versus untreated 
MDA-MB-361, MCF7 and SKBr3 cells. As shown in 
Figure 1: Expression of heregulin and HER3 in claudin-low, luminal and basal A breast cancer cell lines. The breast cancer 
cell lines indicated were cultured to sub-confluence then total RNA was isolated for quantitative RT-PCR analysis of heregulin (neuregulin-1 
α and β splice isoforms: NRG1α and NRG1β) and ERBB3. Data shown are means ± standard deviation. We observed an inverse association 
between ERBB3 and NRG1 with reciprocal expression in luminal compared to claudin-low (basal B) breast cancer cell lines.
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Figure 3A, HRG induced a time-dependent proliferative 
response in MDA-MB-361 and MCF7, but not SKBr3 
cells. Others have demonstrated that HER2 promotes 
proliferation through deregulation of cell cycle check-
points [52]. We therefore investigated the effects of 
HRG on cyclin D1 and p27 protein levels by Western 
blot analysis. As shown in Figure 3B, HRG treatment 
attenuated p27 and induced cyclin D1 expression in the 
two proliferative cell lines.
Tumor cell adhesion to extracellular matrix proteins 
enhances survival and metastatic potential of circulating 
tumor cells [53], and adhesion of circulating tumor cells 
to the brain endothelium is thought to be a critical step 
preceding endothelial retraction and active extravasation 
[54, 55]. To investigate whether HER2-HER3 signaling 
increases the adhesive properties of luminal breast cancer 
cell lines, we assayed adhesion of HRG-treated cells to 
collagen I, which is a substrate for a range of cell adhesion 
molecules. HRG enhanced the adhesion of MDA-MB-361 
and SKBr3 cells to collagen I (Figure 4A), concomitant 
with induction of ICAM-1 (Figure 4B–4C), a β2-integrin 
receptor associated with enhanced invasion, motility and 
metastasis in breast cancer [56–58]. Collectively these 
data show that exogenous HRG promotes proliferation and 
adhesion of luminal breast cancer cell lines, though these 
responses could be context-dependent since they were not 
consistent across the cell lines tested.
Exogenous HRG induces luminal breast cancer 
cell line invasion and secreted protease activity
AKT signaling induces aggressive breast cancer cell 
behavior and others have reported that HRG induces motility 
and invasion through ECM proteins (e.g. [50, 59–61]). 
Consistent with this, transwell assay experiments showed 
that the three cell lines migrated toward a HRG chemotactic 
signal (Figure 5A). Moreover, this response was maintained 
after coating the transwell inserts with matrigel (Figure 5B). 
These data show that HRG promotes both migratory and 
invasive behavior of luminal breast cancer cell lines, which 
otherwise migrate very poorly in vitro.
Since this invasive activity requires remodeling of 
ECM proteins, and AKT-associated invasion is marked by 
secretion of several proteases that are important in invasion 
and metastasis [62], we next investigated expression 
of MMP-2, MMP-9, urokinase plasminogen activator 
receptor (PLAU; uPAR) and its ligand (PLAUR; uPA), and 
cathepsin B (CSTB) in the HRG-treated cells. Using qRT-
PCR analysis we found HRG induced cell line-dependent 
increases in expression of MMP2, PLAUR and PLAU, and 
Figure 2: Treatment of luminal HER2+ breast cancer cell lines with exogenous HRG alters cell morphology and 
activates signaling through HER2, HER3, AKT and ERK. (A) Serum-starved cells were treated with HRG for 48 h then imaged 
by light microscopy (images acquired at 20x magnification). (B) Serum-starved cells were treated with HRG for 30 min then total and 
phosphorylated HER, AKT and ERK isoforms were quantified by Western blot. β-actin was used as the loading control.
Oncotarget3936www.impactjournals.com/oncotarget
a modest but significant decrease in expression of CSTB 
(Figure 6A). MMP9 was consistently induced in all three 
cell lines (Figure 6A). This was also evident at the protein 
level, with Western blot analysis confirming induction of 
MMP-9 protein in all three cell lines, and variable changes 
for the other proteolytic proteins (Figure 6B).
Ultimately we were interested in common HRG-
induced changes in the secretion and extracellular activity 
of ECM proteases, and so we assessed the proteolytic 
activities of MMP-9 and MMP-2 activity in conditioned 
media from the HRG-treated cells by gelatin zymography 
(gelatin is a substrate for both enzymes). This experiment 
confirmed that HRG-mediated induction of MMP-9 was 
associated with activation of extracellular MMP-9 activity 
in cultures of all three cell lines, though the total amount 
was relatively lower in MDA-MB-361 compared to 
SKBr3 and MCF7 cells (Figure 6C). MMP-2 activity was 
induced in MDA-MB-361 and SKBr3 cells.
Others have previously reported that in both breast 
tumors and cell lines, there is a negative association 
between the expression of MMP-9 and one of its natural 
Figure 3: Effects of HRG on proliferation of luminal 
HER2+ breast cancer cell lines. (A) Serum-starved cells 
were treated with HRG and proliferation rate was assessed using 
an MTT assay over the following 72 h. Data shown are means 
± standard deviation, normalised to an untreated control group 
for each cell line at each timepoint. ***p < 0.0001 according to 
unpaired, 2-tailed student’s t-tests comparing treated vs untreated 
cells at 72 hours post-treatment. FC, fold-change. (B) Serum-
starved cells were treated with HRG for 48 h, then expression 
of p27 and cyclin D1 proteins was quantified by Western blot 
(loading control: α-tubulin).
Figure 4: Effects of HRG on adhesive abilities of 
luminal HER2+ breast cancer cell lines. (A) HRG 
increases adhesion of MDA-MB-361 and SKBr3 cells to 
collagen-I. Serum-starved cells were treated with HRG for 48 
h, allowed to adhere to collagen-I-coated dishes for 15 min 
then adhesion potential was determined using optical density 
measurements of treated versus untreated controls. *p = 0.05–
0.01, **p = 0.01–0.001 (2-tailed, unpaired student’s t-tests). 
HRG increases expression of ICAM-1 RNA (B) and protein (C) 
in MDA-MB-361 and SKBr3 cells. Cells were treated as above, 
then total RNA or protein were prepared for quantitative real-
time PCR or Western blot of ICAM-1 expression respectively 
(HPRT1 or α-tubulin loading controls, respectively). **p = 
0.001–0.0001; ***p < 0.0001 (2-tailed, unpaired student’s 
t-tests). FC, fold-change.
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inhibitors, RECK [30], a key breast cancer metastasis 
suppressor gene. Furthermore, RECK is repressed in 
brain metastases compared to primary breast cancers 
[63]. The KAI1 (CD82) metastasis suppressor has also 
been implicated in MMP-9 repression [64]. We therefore 
investigated expression of KAI1 and RECK by qRT-PCR 
and found that HRG treatment repressed both genes 
(Figure 6D), suggesting this could be one mechanism 
by which HRG increases extracellular MMP-9 activity. 
Interestingly, the two RECK-suppressed cell lines (MDA-
MB-361 and SKBr3) are ERBB2-amplified, and RECK is 
known to functionally oppose oncogenic HER2 signaling 
by interfering with HER3 dimerization [65].
Finally, we investigated the expression and activity 
of extracellular cathepsin B, as this has been implicated 
in mediating invasive behavior of HER2-positive breast 
cancer cells [66], and activation of MMP-9 and infiltrative 
tumor cell growth in glioma [67–69]. There was no 
substantial change in cathepsin B expression following 
treatment with exogenous HRG (Figure 6E), but there was 
a significant increase in extracellular cathepsin B activity 
in all three breast cancer cell lines (Figure 6F). Others 
have shown that PI3K mediates cathepsin B secretion by 
lysosomal exocytosis [70], and therefore increased secretion 
of cathepsin B may be one mechanism by which HRG 
increases its extracellular activity in breast cancer cell lines.
Exogenous HRG induces transmigration of breast 
cancer cell lines across a tight barrier of primary 
human brain microvascular endothelial cells
MMP-2 and MMP-9 have been associated with 
degradation of endothelial tight junction proteins, 
permeabilization of the blood-brain-barrier (BBB) 
and subsequent brain colonization in mouse models 
of leukemia [71]. Therefore we investigated whether 
active MMP isoforms in conditioned media from HRG-
treated breast cancer cell lines are sufficient to stimulate 
transmigration across an endothelial barrier. We established 
an in vitro model of the BBB using primary human brain 
Figure 5: Luminal HER2+ breast cancer cell lines invade across matrigel toward a heregulin chemotactic signal. Serum-
starved cells were seeded in 8 μm transwell chambers (A) or 8 μm transwell chambers in which the membranes were pre-coated with 
matrigel (B). HRG was supplemented in the lower chamber, and media was changed regularly to maintain a concentration gradient. After 
48 h, cells on the lower surfaces of the porous membranes were quantified by crystal violet staining. Data shown are means ± standard 
deviation, normalised to the untreated control group for each cell line. **p = 0.05–0.01, **p = 0.01–0.001 (unpaired, 2-tailed student’s 
t-tests of HRG-treated cells compared to untreated controls). FC, fold-change.
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microvascular endothelial cells (HBMECs) and matrigel to 
simulate the brain endothelium and basement membrane 
respectively (Figure 7A). The integrity of this barrier 
was validated by measuring dextran-FITC diffusion 
(Figure 7B), and by confirming strong induction of tight 
junction proteins claudin-5, ZO-1 and occludin in the 
HBMEC layer (Figure 7C) as described [72].
Treatment of co-cultured breast cancer cell lines with 
exogenous HRG (Figure 7A) caused active migration of all 
three cell lines across the tight HBMEC layer (Figure 7D). 
This response was attenuated upon inhibition of HER2, 
HER3 or MMP activity, assessed by supplementing the 
upper chambers with saturating doses of humanized 
monoclonal antibodies against HER2 and HER3 
Figure 6: Treatment of luminal breast cancer cell lines with exogenous HRG increases extracellular protease 
activity. (A, B) HRG increases expression of proteolytic cascade proteins. Serum-starved cells were treated with HRG for 48 h, then 
total RNA or protein were isolated from the cells for qRT-PCR and Western blot analyses respectively (HPRT1 and α-tubulin were used 
as normalization and loading controls, respectively). (C) HRG increases secreted MMP-2 and MMP-9 proteolytic activities. Starved cells 
were treated with HRG as above and then conditioned media was concentrated and analysed for MMP-2 and MMP-9 activity by gelatin 
zymography (enzymatic activity is proportional to the intensity of the white bands). (D) HRG represses expression of RECK and KAI1 
metastasis suppressor genes. qRT-PCR analysis was performed as for (A). HRG treatment does not substantially alter cathepsin B protein 
expression (E), but increases extracellular cathepsin B proteolytic activity (F). Cathepsin B expression was analyzed by Western blot analysis 
as for (B), with β-actin as the loading control. Enzyme activity was assayed using a fluorometric enzyme activity assay. *p = 0.01–0.001, 
**p = 0.001–0.0001, ***p < 0.0001 (unpaired, 2-tailed student’s t-tests comparing treated to untreated control samples). FC, fold-change.
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(Herceptin® and EV20 respectively) or the broad-spectrum 
MMP inhibitor, GM6001. Treatment with GM6001 did not 
completely abrogate the response, indicating that MMPs 
may not be the only transmigration mechanism activated 
by HRG-HER3-HER2 signaling. It is noteworthy that 
complete inhibition of transmigratory activity was only 
achieved through combined blockade of HER2 and HER3 
(Herceptin® + EV20; Figure 7D, green lines).
DISCUSSION
The development of brain metastases is a 
devastating complication that affects 10–30% of women 
with breast cancer [2], causing challenging neurological 
symptoms including headaches, cognitive impairment 
and seizures [73]. Current treatments can prolong life 
expectancy and improve quality-of-life, though ultimately 
Figure 7: Treatment of luminal breast cancer cell lines with exogenous HRG increases their endothelial transmigration 
activity. (A) Schematic of the in vitro blood-brain-barrier model used to assay transendothelial migration of HRG-treated breast cancer 
cell lines (blue lines = tight junctions). Primary human brain microvascular endothelial cells (HBMECs) were seeded into matrigel-coated 
transwell chambers, then allowed to form a confluent layer. Serum-starved breast cancer cell lines were then seeded over the layer). (B) 
The functional integrity of the HBMEC layer was validated by measuring dextran-FITC (40 kDa) flux from the upper to lower transwell 
chambers. (C) HBMEC expression of tight junction proteins in layer-forming culture conditions was confirmed by Western blot analysis. 
(D) Breast cancer cell line transendothelial migration activity was measured in response to HRG ligand with and without drug treatments as 
indicated. Data shown are means ± standard deviation (n = 3 from a representative experiment). The statistical significance of differences 
between treatments and the untreated control was determined using unpaired, 2-tailed student’s t-tests (*p = 0.05–0.01, **p = 0.01–0.001 
and ***p < 0.001). BCa, breast cancer; FC, fold-change; mAb, monoclonal antibody; MMPi, matrix metalloproteinase inhibitor.
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they are not curative. Molecular targeted drug therapy 
is critically under-utilized in the clinic, partly because 
of deficiencies in our understanding of the molecular 
mechanisms involved in the seeding and subsequent 
proliferation of disseminated cells in the brain. Research 
in this area is now beginning to illuminate some of the 
mechanisms by which tumor cells exploit and remodel the 
local microenvironment to facilitate metastatic outgrowth 
[40–42, 74–76].
Heregulin is critical for the normal development 
and function of the nervous system. It is expressed by 
neurons, glia and brain microvascular endothelia, where 
its functions include promoting glial cell survival and 
differentiation, neural precursor cell differentiation and 
migration, and endothelial cell protection from oxidative 
injury [18–20]. Consistent with the idea that HRG is a 
brain growth factor exploited by metastatic cells, HER3 
is induced and activated in brain metastases compared to 
matching breast and lung cancers [23, 24] and patients 
with HER2-positive breast cancer are at high risk of 
brain relapse [4, 6]. Moreover, primary breast cancers 
over-expressing HER3 are more likely to relapse as 
isolated brain metastases than non-HER3-overexpressing 
tumors [22].
In this study, we found that exposure to HRG 
stimulated the transendothelial migration of HER2/3-
expressing breast cancer cell lines across a tight barrier 
of primary human brain microvascular endothelia and 
an associated matrigel layer, and that this was at least 
partly mediated by MMPs (Figure 7). Specifically, 
exposure to HRG increased the extracellular activity of 
MMP-9 in three cell lines, and MMP-2 in two of these 
lines (Figure 6). Other studies have implicated MMP-2 
and -9 in the development of brain metastases [31–34], 
and the current study now suggests that this could be at 
least partly due to enhancing vascular permeability. Since 
HRG is expressed by brain microvascular endothelia [20], 
these data raise the possibility that HRG-HER3-HER2 
signaling is involved in extravasation from the brain 
microvasculature in vivo, particularly since we also found 
that HRG increases breast cancer cell adhesion potential 
(Figure 4). Indeed, MMPs 2 and 9 can mediate vascular 
leakage in experimental models of cerebral ischemic 
injury by degrading endothelial tight junction complexes 
[77–79]. HRG-mediated vascular permeabilization could 
also be important in established metastases with increasing 
metabolic demands.
Adjuvant Herceptin® therapy for HER2-positive 
breast cancer delays the onset of brain metastases [10], and 
this latency is further extended by the HER2 dimerization 
blocker Perjeta® [8]. In this context, it is noteworthy that 
Herceptin® and the humanized HER3 antibody EV20 
[80] conferred additive suppression of transmigration 
in our blood-brain-barrier experiments (Figure 7). 
There are likely to be multiple mechanisms enabling 
endothelial transmigration and consequent establishment 
of micrometastases in vivo (for example, we also found 
that exposure to exogenous HRG reduces expression of 
KAI1 and RECK metastasis suppressor genes), however 
these in vitro experiments may provide some molecular 
insight into the aforementioned clinical observations.
The cell lines used in this study all migrated and 
invaded through extracellular matrix proteins towards an 
HRG chemotactic signal (Figure 5), concomitant with 
increased activity of extracellular proteases (Figure 6). 
Consistent with other reports [60, 81], we observed cell 
proliferation in response to HRG exposure (Figure 3). 
Collectively these data suggest that HRG-HER3-HER2 
signaling could be involved in several aspects of brain 
metastasis development. In vivo experiments modeling 
these steps with inhibition of HER2-HER3 dimer function 
are required in the future.
This study has potential implications in translational 
oncology, and warrants further investigation into the 
possibility of targeting the HRG-HER3-HER2 axis for 
management of brain metastases from HER2-positive 
breast cancer.
MATERIALS AND METHODS
Breast cancer cell lines and HRG activation assay
The breast cancer cell lines used in this study were 
obtained from the American Type Culture Collection 
(ATCC). The panel of cell lines included three molecular 
subtypes previously defined by expression array profiling 
and unsupervised cluster analysis and/or surrogate 
immunohistochemical markers [44–46]: claudin-low 
(basal B): MDA-MB-436, MDA-MB-231, RHB1, 
184B5, MCF10A, 184A1, SUM159, Hs578T, HBL100 
and BT549; basal-A: HCC70, MDA-MB-468, Bre80Tert, 
HCC1937, HCC1143, SVCT, PMC-42-ET; luminal: 
MCF7, KPL-1, T-47D, ZR751, MDA-MB-175-VII); 
and luminal/ERBB2-amplified: MDA-MB-453, BT-474, 
SKBr3 and MDA-MB-361. MDA-MB-361 is the only 
commercially available breast cancer cell line that was 
derived from a metastatic brain tumor. All cell lines 
were authenticated by STR profiling (Cell ID™ system; 
Promega) and were routinely checked for mycoplasma 
infection (MycoAlert™; Lonza). Cell cultures were 
maintained at 37°C in 5% CO2 in a humidified incubator 
and cultured according to ATCC recommendations.
For heregulin (HRG) activation experiments, cells 
were routinely seeded at predetermined densities in regular 
culture medium, then switched from the recommended 
amount of fetal bovine serum (FBS) to 0.1% FBS 
(serum-starved conditions) for 24 hours. Cultures were 
then supplemented with 50 ng/mL HRG-β1 (Sigma) and 
cultured for either 30 min (signaling analysis) or 48 h 
(functional experiments including assaying expression of 
downstream targets of HER2-HER3 signaling).
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Analysis of gene expression by quantitative real 
time reverse transcription-PCR (qRT-PCR)
Trizol (Invitrogen) was used to isolate total RNA 
from cultured cells. cDNA was prepared using 1 μg of 
RNA from each sample with the PrimeScript RT reagent 
kit (Takara Bio Inc.). qPCR was then performed in 
triplicate on a StepOnePlus instrument using SYBR green 
(Applied Biosystems) according to standard procedures 
(see Table 1 for PCR primers). Melt curve analysis was 
performed to verify amplification of single PCR products. 
Hypoxanthine phosphoribosyl transferase1 (HPRT1) was 
amplified as normalizer and fold change in expression 
of each target mRNA relative to HPRT1 was calculated 
according to the 2–ΔΔct relative expression formula [82]. 
HER3 qPCR was performed using the ERBB3 TaqMan® 
expression assay (Hs00951455_m1; Applied Biosystems).
Western blot analysis
Total protein extracts were prepared in RIPA buffer 
(50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1.0% NP-40, 
0.5% sodium deoxycholate and 0.1% SDS) containing fresh 
protease and phosphatase inhibitors (Thermo Scientific) for 
30 min at 4°C. Thirty to fifty μg of lysate was resolved by 
SDS-PAGE, transferred to PVDF membrane (Immobilin P, 
Millipore) then probed with primary antibodies (Table 2) 
followed by horseradish peroxidase (HRP)-conjugated 
secondary antibodies (Sigma). Two different HER3 
antibodies were used to confirm the increase in HER3 
protein levels 30 min after HRG treatment. Blots were 
probed with α-tubulin and β-actin as loading controls.
Cell proliferation assay
A microculture tetrazolium test (MTT) was 
performed to determine cell proliferation after treatment 
of the cells with recombinant HRG. Briefly, cells were 
plated onto 96-well plates at a density of 4×104/well for 
24 h and then starved in 0.1% FBS for 24 h. The cells were 
then treated with 50 ng/mL of HRG for 24, 48 and 72 h. 
Untreated cells were used as the control group. 100 μL 
of MTT (0.5 mg/ml) (Sigma) was added to each well 
and the cultures were further incubated at 37°C for 2 h. 
After dissolving the precipitated formazan with 100 μL 
of dimethyl sulfoxide (DMSO), the optical density was 
measured at 570 nm.
Cell adhesion assay
Adhesion experiments were conducted as described 
[14]. Cells were seeded into 6-well plates and after 24 h, 
washed three times with PBS and starved in 0.1% FBS 
overnight. The starved cells were treated with 50 ng/mL 
HRG for 48 h and seeded on collagen I coated 60 mm dishes 
(Biocoat Cell Environments; Becton Dickinson). After 15 
min, cells were washed with cold PBS, stained with 0.5% 
crystal violet, lysed with 30% acetic acid and the optical 
density was measured at 590 nm.
Gelatin zymography
Gelatin zymography was carried out as described 
[83]. Briefly, conditioned media from HRG-treated and 
untreated cells was collected and centrifuged at high 
speed for 10 min to pellet cell debris. Protein from the 
conditioned media was then concentrated as appropriate 
using a Vacufuge® plus (Eppendorf). Five μg of secreted 
protein were applied to 10% polyacrylamide gels 
copolymerized with 1 mg/mL gelatin (Sigma). After 
electrophoresis, gels were rinsed in 2.5% Triton X-100 
(3×30 min) to remove SDS, followed by incubation 
at 37°C overnight in incubation buffer (0.15 M NaCl, 
10 mM CaCl2, 0.02% NaN3 in 50 mM Tris-HCl, pH 7.5). 
Gels were then stained (0.5% Coomassie Brilliant Blue) 
and destained with 7% methanol and 5% acetic acid. 
Areas of enzymatic activity appeared as clear bands over 
the dark background.
Cell migration and invasion assays
Cell migration was assayed in 24-well, 6.5-mm-
internal-diameter transwell plates (8.0 μm pore size; 
Costar Corp.). Serum-starved cells were placed in the 
upper chambers, and the lower chamber was filled with 
media containing 0.1% FBS (control), with or without 
HRG supplementation (50 ng/mL). Media in both 
chambers was changed every 6 hours to maintain an HRG 
gradient. Cells were allowed to migrate for 48 h. After 
this time, cells on the upper surfaces of the filters were 
removed by wiping with a cotton swab and migrated cells 
on the undersides of the filters were fixed with methanol, 
stained with crystal violet, lysed with 30% acetic acid and 
the optical density was measured at 590 nm. For invasion, 
experiments were essentially conducted as above, except 
that transwell filters were pre-coated with matrigel (1:10 
dilution in media; BD Biosciences).
Cathepsin B activity assay
To investigate the effect of HRG on the activity 
of secreted cathepsin B, conditioned media from HRG-
treated and untreated cells was centrifuged at 10,000 
rpm for 15 min to remove cell debris, then concentrated 
appropriately using the Vacufuge® plus (Eppendorf). We 
used a fluorometric cathepsin B activity assay (Abcam) 
according to the manufacturer’s instructions.
Blood-brain-barrier transendothelial migration 
assay
Primary human brain microvascular endothelial 
cells (HBMECs) and HBMEC culture reagents were 
purchased from Cell Systems and cells were routinely 
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Table 1: Primers used for qRT-PCR
Gene Accession no. Forward primer (5′-3′) Reverse primer (5′-3′)
NRG1α NM_013964 AAACCAAGAAAAGGCGGAGGAGCT GAGGGCGATGCAGATGCCGG
NRG1β NM_013956 GCCAGCTTCTACAAGCATCTTGGGA GGAGGGCGATGCAGATGCCG
HPRT1 NM_000194 TGGACAGGACTGAACGTCTTG CCAGCAGGTCAGCAAAGAATTTA
MMP2 NM_004530 CTTCCAAGTCTGGAGCGATGT TACCGTCAAAGGGGTATCCAT
MMP9 NM_004994 GGGACGCAGACATCGTCATC TCGTCATCGTCGAAATGGGC
PLAU (uPA) NM_002658 TCAAAAACCTGCTATGAGGGGA GGGCATGGTACGTTTGCTG
PLAUR (uPAR) NM_002659 TGTAAGACCAACGGGGATTGC AGCCAGTCCGATAGCTCAGG
KAI1 NM_002231 GCCGACAAGAGCAGTTTCATC AGGAAAGCAAAGTACAGCCCC
RECK NM_021111 TGTGAACTGGCTATTGCCTTG GCATAACTGCAACAAACCGAG
ICAM1 NM_000201 TTGGGCATAGAGACCCCGTT GCACATTGCTCAGTTCATACACC
CSTB NM_147780 CTGTCGGATGAGCTGGTCAAC TCGGTAAACATAACTCTCTGGGG
Table 2: Primary antibodies used for western blot analysis
Antigen Clone Supplier
HER3 2F12 Millipore
HER3 C-17 Santa Cruz
HER2 Polyclonal Millipore
pHER2Y1248 Polyclonal Cell Signaling Technology
pHER3Y1289 21D3 Cell Signaling Technology
Akt Polyclonal Cell Signaling Technology
pAktS473 D9E Cell Signaling Technology
ERK1/2 137F5 Cell Signaling Technology
p-ERK1/2T202/Y204 197G2 Cell Signaling Technology
Cathepsin B G60 Cell Signaling Technology
Cyclin D1 H-295 Santa Cruz Biotechnology
ICAM-1 H-108 Santa Cruz Biotechnology
p27 C-19 Santa Cruz Biotechnology
MMP-9 Polyclonal Sigma
uPA H-140 Sigma
uPAR Polyclonal Sigma
ZO-1 ZO1-1A12 Invitrogen
Occludin OC-F10 Invitrogen
α-tubulin 4G1 Abcam
β-actin 8H10D10 Cell Signaling Technology
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cultured in CSC Complete Medium on fibronectin 
(Invitrogen) pre-coated surfaces, according to the 
manufacturer’s recommendations. Two×104 HBMECs 
were seeded on matrigel-coated 0.4 μm transwell filters 
(Costar Corp.) in 200 μL of CSC complete medium. 
The lower compartment was filled with 600 μL of 
the same medium. Cells were grown for 4 d to allow 
complete formation of HBMEC tight junctions (TJs). 
The impermeability of this in vitro BBB model to 
small solutes was assayed by measuring dextran-FITC 
(Invitrogen) flux from the top to bottom chambers. 
The media was changed to 1% FBS-CSC media plus 
CultureBoost (Cell Systems) for 24 h. Dextran-FITC 
(1 mg/mL; Invitrogen) was added to the upper chamber 
and after 20 min, 50 μL media from upper and lower 
chambers was removed and fluorescence was measured 
using a Paradigm™ Detection Platform (Beckman 
Coulter; 485 nm excitation, 520 nm emission).
For transmigration assays, 2×104 HBMEC cells 
were seeded into matrigel-coated (BD Biosciences) 24-
well transwell inserts (8 μm pores; Costar Corp.). The 
cells were maintained for 4 d to allow the TJ formation, 
then media from upper and lower chambers was changed 
to 1% FBS-CSC media plus CultureBoost for 24 h (as 
above). Serum-starved breast cancer cell lines (1×105 for 
MCF7 and SKBr3, or 2×105 for MDA-MB-361) were 
seeded into the upper chamber in 100 μL of their regular 
media containing 0.1% FBS, then allowed to attach 
for 2 h. Cultures were then treated with HRG, (50 ng/mL; 
Sigma), GM6001 (20 μg/mL; Calbiochem), Herceptin® 
(20 μg/mL; Experimental Pharmacology Oncology, 
Berlin) and/or EV20 (20 μg/mL; Mediapharma) for 48 
h. The upper surfaces of the transwell filters were then 
gently wiped clean with a cotton swab to remove non-
migrating cells and cells on the undersides were fixed 
with methanol, stained with crystal violet, lysed with 
30% acetic acid and the optical density was measured 
at 590 nm
Statistical analysis
Data are expressed as mean ± standard deviation 
(SD). All experiments were performed in triplicate. For 
statistical analysis, unpaired, two-tailed t-tests were 
applied. P values of less than 0.05 were considered 
significant.
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